Schistosoma	B-OG
mansoni	I-OG
Soluble	O
Egg	O
Antigens	O
Induce	O
Expression	O
of	O
the	O
Negative	O
Regulators	O
SOCS1	B-GP
and	O
SHP1	B-GP
in	O
Human	B-OG
Dendritic	O
Cells	O
via	O
Interaction	O
with	O
the	O
Mannose	B-GP
Receptor	I-GP

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
EJK	O
LK	O
RDC	O
IVD	O
.	O

Performed	O
the	O
experiments	O
:	O
EJK	O
LK	O
.	O

Analyzed	O
the	O
data	O
:	O
EJK	O
LK	O
IVD	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
TKL	O
RDC	O
.	O

Wrote	O
the	O
paper	O
:	O
EJK	O
RDC	O
IVD	O
.	O

Schistosomiasis	B-DS
is	O
a	O
common	O
debilitating	O
human	B-OG
parasitic	B-DS
disease	I-DS
in	O
(	O
sub	O
)	O
tropical	O
areas	O
,	O
however	O
,	O
schistosome	B-DS
infections	I-DS
can	O
also	O
protect	O
against	O
a	O
variety	O
of	O
inflammatory	B-DS
diseases	I-DS
.	O

This	O
has	O
raised	O
broad	O
interest	O
in	O
the	O
mechanisms	O
by	O
which	O
Schistosoma	B-OG
modulate	O
the	O
immune	O
system	O
into	O
an	O
anti	O
-	O
inflammatory	O
and	O
regulatory	O
state	O
.	O

Human	B-OG
dendritic	O
cells	O
(	O
DCs	O
)	O
show	O
many	O
phenotypic	O
changes	O
upon	O
contact	O
with	O
Schistosoma	B-OG
mansoni	I-OG
soluble	O
egg	O
antigens	O
(	O
SEA	O
).	O

We	O
here	O
show	O
that	O
oxidation	O
of	O
SEA	O
glycans	O
,	O
but	O
not	O
heat	O
-	O
denaturation	O
,	O
abrogates	O
the	O
capacity	O
of	O
SEA	O
to	O
suppress	O
both	O
LPS	O
-	O
induced	O
cytokine	B-GP
secretion	O
and	O
DC	O
proliferation	O
,	O
indicating	O
an	O
important	O
role	O
of	O
SEA	O
glycans	O
in	O
these	O
processes	O
.	O

Remarkably	O
,	O
interaction	O
of	O
SEA	O
glycans	O
with	O
DCs	O
results	O
in	O
a	O
strongly	O
increased	O
expression	O
of	O
Suppressor	B-GP
Of	I-GP
Cytokine	I-GP
Signalling1	I-GP
(	O
SOCS1	B-GP
)	O
and	O
SH2	B-GP
-	I-GP
containing	I-GP
protein	I-GP
tyrosine	I-GP
Phosphatase	I-GP
-	I-GP
1	I-GP
(	O
SHP1	B-GP
),	O
important	O
negative	O
regulators	O
of	O
TLR4	B-GP
signalling	O
.	O

In	O
addition	O
,	O
SEA	O
induces	O
the	O
secretion	O
of	O
transforming	B-GP
growth	I-GP
factor	I-GP
β	I-GP
(	O
TGF	B-GP
-	I-GP
β	I-GP
),	O
and	O
the	O
surface	O
expression	O
of	O
the	O
costimulatory	O
molecules	O
Programmed	B-GP
Death	I-GP
Ligand	I-GP
-	I-GP
1	I-GP
(	O
PD	B-GP
-	I-GP
L1	I-GP
)	O
and	O
OX40	B-GP
ligand	I-GP
(	O
OX40L	B-GP
),	O
which	O
are	O
known	O
phenotypic	O
markers	O
for	O
the	O
capacity	O
of	O
DCs	O
to	O
polarize	O
naïve	O
T	O
cells	O
into	O
Th2	O
/	O
Treg	O
cell	O
subsets	O
.	O

Inhibition	O
of	O
mannose	B-GP
receptor	I-GP
(	O
MR	B-GP
)-	O
mediated	O
internalization	O
of	O
SEA	O
into	O
DCs	O
by	O
blocking	O
with	O
allyl	O
α	O
-	O
D	O
-	O
mannoside	O
or	O
anti	O
-	O
MR	B-GP
antibodies	B-GP
,	O
significantly	O
reduced	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
SEA	O
glycans	O
are	O
essential	O
for	O
induction	O
of	O
enhanced	O
SOCS1	B-GP
and	O
SHP1	B-GP
levels	O
in	O
DCs	O
via	O
the	O
MR	B-GP
.	O

Our	O
data	O
provide	O
novel	O
mechanistic	O
evidence	O
for	O
the	O
potential	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
glycans	O
to	O
modulate	O
human	B-OG
DCs	O
,	O
which	O
may	O
contribute	O
to	O
the	O
capacity	O
of	O
SEA	O
to	O
down	O
-	O
regulate	O
inflammatory	O
responses	O
.	O

Introduction	O

Parasitic	O
helminths	B-OG
(	O
worms	B-OG
)	O
have	O
evolved	O
to	O
suppress	O
inflammatory	O
responses	O
of	O
the	O
immune	O
system	O
to	O
survive	O
in	O
their	O
hosts	O
[	O
1	O
].	O

Interestingly	O
,	O
these	O
properties	O
have	O
equipped	O
them	O
with	O
the	O
capacity	O
to	O
reduce	O
the	O
severity	O
of	O
inflammatory	B-DS
diseases	I-DS
within	O
that	O
host	O
[	O
1	O
,	O
2	O
].	O

Evidence	O
from	O
epidemiological	O
studies	O
indicates	O
an	O
inverse	O
relationship	O
between	O
the	O
incidence	O
of	O
helminth	B-DS
infections	I-DS
and	O
the	O
occurrence	O
of	O
immune	B-DS
-	I-DS
related	I-DS
diseases	I-DS
including	O
allergies	B-DS
,	O
multiple	B-DS
sclerosis	I-DS
(	O
MS	B-DS
)	O
and	O
inflammatory	B-DS
bowel	I-DS
disease	I-DS
(	O
IBD	B-DS
)	O
[	O
3	O
,	O
4	O
,	O
5	O
].	O

In	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
,	O
a	O
mouse	B-OG
model	O
for	O
MS	B-DS
,	O
eggs	O
of	O
Schistosoma	B-OG
mansoni	I-OG
,	O
a	O
parasitic	O
trematode	B-OG
bloodfluke	B-OG
,	O
reduced	O
disease	O
severity	O
in	O
established	O
disease	O
,	O
while	O
pre	O
-	O
established	O
infection	B-DS
with	O
live	O
S	B-OG
.	I-OG
mansoni	I-OG
delayed	O
onset	O
and	O
significantly	O
reduced	O
incidence	O
of	O
the	O
disease	O
[	O
6	O
].	O

In	O
TNBS	O
and	O
DSS	O
colitis	B-DS
models	O
,	O
two	O
mouse	B-OG
models	O
for	O
IBD	B-DS
,	O
S	B-OG
.	I-OG
mansoni	I-OG
was	O
shown	O
to	O
ameliorate	O
colitis	B-DS
[	O
7	O
,	O
8	O
]	O
and	O
infection	B-DS
with	O
S	B-OG
.	I-OG
mansoni	I-OG
has	O
beneficial	O
effects	O
in	O
collagen	B-GP
-	O
induced	O
arthritis	B-DS
[	O
9	O
].	O

The	O
effect	O
of	O
helminths	B-OG
to	O
reduce	O
the	O
severity	O
of	O
inflammation	O
within	O
their	O
host	O
has	O
been	O
attributed	O
to	O
their	O
capacity	O
to	O
modulate	O
the	O
host	O
’	O
s	O
immune	O
response	O
.	O

A	O
key	O
cell	O
type	O
in	O
this	O
pathway	O
is	O
the	O
dendritic	O
cell	O
(	O
DC	O
),	O
which	O
is	O
an	O
antigen	O
-	O
presenting	O
cell	O
that	O
plays	O
a	O
central	O
role	O
within	O
the	O
immune	O
system	O
in	O
determining	O
the	O
type	O
of	O
effector	O
T	O
cell	O
response	O
via	O
the	O
recognition	O
of	O
pathogen	O
-	O
derived	O
or	O
self	O
-	O
antigens	O
.	O

DCs	O
are	O
well	O
equipped	O
to	O
govern	O
the	O
development	O
of	O
naïve	O
T	O
helper	O
(	O
Th	O
)	O
cells	O
towards	O
Th1	O
,	O
Th2	O
,	O
or	O
regulatory	O
T	O
cell	O
(	O
Treg	O
)	O
phenotypes	O
,	O
depending	O
on	O
the	O
information	O
that	O
is	O
received	O
from	O
sampled	O
antigens	O
.	O

LPS	O
-	O
activated	O
DCs	O
polarize	O
naïve	O
T	O
cells	O
towards	O
a	O
Th1	O
response	O
,	O
by	O
production	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
such	O
as	O
interleukin	B-GP
12	I-GP
(	O
IL	B-GP
-	I-GP
12	I-GP
).	O

On	O
the	O
other	O
hand	O
,	O
infection	B-DS
with	O
helminths	B-OG
like	O
S	B-OG
.	I-OG
mansoni	I-OG
leads	O
to	O
Th2	O
and	O
Treg	O
responses	O
,	O
driven	O
by	O
DCs	O
among	O
other	O
cells	O
,	O
via	O
the	O
increase	O
in	O
IL	B-GP
-	I-GP
10	I-GP
and	O
/	O
or	O
transforming	B-GP
growth	I-GP
factor	I-GP
β	I-GP
(	O
TGF	B-GP
-	I-GP
β	I-GP
)	O
levels	O
,	O
and	O
surface	O
expression	O
of	O
specific	O
costimulatory	O
molecules	O
like	O
Programmed	B-GP
Death	I-GP
Ligands	I-GP
(	O
PD	B-GP
-	I-GP
L1	I-GP
/	O
2	O
)	O
and	O
OX40	B-GP
ligand	I-GP
(	O
OX40L	B-GP
)	O
[	O
10	O
,	O
11	O
,	O
12	O
,	O
13	O
].	O

DCs	O
acquire	O
immune	O
regulatory	O
functions	O
by	O
interaction	O
with	O
pathogens	O
,	O
including	O
helminths	B-OG
,	O
via	O
various	O
pattern	B-GP
-	I-GP
recognition	I-GP
receptors	I-GP
,	O
such	O
as	O
toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
)	O
and	O
C	B-GP
-	I-GP
type	I-GP
lectin	I-GP
receptors	I-GP
(	O
CLRs	B-GP
)	O
[	O
14	O
].	O

In	O
this	O
study	O
we	O
focus	O
on	O
defining	O
molecular	O
mechanisms	O
that	O
contribute	O
to	O
the	O
suppression	O
of	O
inflammatory	O
responses	O
of	O
human	B-OG
DCs	O
by	O
S	B-OG
.	I-OG
mansoni	I-OG
soluble	O
egg	O
antigens	O
(	O
SEA	O
).	O

Several	O
studies	O
have	O
shown	O
that	O
production	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
by	O
TLR	B-GP
-	O
stimulated	O
human	B-OG
DCs	O
is	O
markedly	O
reduced	O
in	O
response	O
to	O
direct	O
contact	O
with	O
SEA	O
[	O
15	O
,	O
16	O
,	O
17	O
].	O

We	O
have	O
shown	O
previously	O
that	O
SEA	O
-	O
primed	O
human	B-OG
DCs	O
induce	O
a	O
Th2	O
response	O
in	O
vitro	O
,	O
associated	O
with	O
increased	O
expression	O
of	O
OX40L	B-GP
on	O
DCs	O
in	O
the	O
presence	O
of	O
LPS	O
[	O
17	O
,	O
18	O
].	O

Interestingly	O
,	O
Omega	B-GP
-	I-GP
1	I-GP
,	O
a	O
major	O
component	O
of	O
SEA	O
,	O
can	O
condition	O
DCs	O
into	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
with	O
potential	O
to	O
induce	O
a	O
Th2	O
response	O
,	O
which	O
is	O
proposed	O
to	O
occur	O
mainly	O
via	O
its	O
RNase	B-GP
action	O
[	O
19	O
,	O
20	O
].	O

Other	O
compounds	O
within	O
SEA	O
include	O
IPSE	B-GP
/	I-GP
α	I-GP
-	I-GP
1	I-GP
,	O
which	O
has	O
been	O
shown	O
to	O
induce	O
IL	B-GP
-	I-GP
4	I-GP
production	O
[	O
21	O
]	O
and	O
Kappa	O
-	O
5	O
[	O
22	O
],	O
however	O
many	O
compounds	O
are	O
still	O
unidentified	O
.	O

DCs	O
stimulated	O
with	O
miracidial	O
fluid	O
secreted	O
by	O
S	B-OG
.	I-OG
mansoni	I-OG
inhibit	O
human	B-OG
T	O
lymphocyte	O
proliferation	O
in	O
mixed	O
lymphocyte	O
reactions	O
(	O
MLR	O
)	O
[	O
23	O
],	O
indicating	O
a	O
reduction	O
of	O
the	O
strength	O
of	O
the	O
immune	O
response	O
.	O

The	O
underlying	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
SEA	O
modulates	O
human	B-OG
DCs	O
,	O
however	O
,	O
are	O
still	O
incompletely	O
understood	O
and	O
likely	O
include	O
multiple	O
SEA	O
components	O
and	O
pathways	O
.	O

In	O
vivo	O
mouse	B-OG
models	O
have	O
shown	O
that	O
the	O
glycosylation	O
of	O
SEA	O
is	O
essential	O
for	O
its	O
ability	O
to	O
induce	O
anti	O
-	O
inflammatory	O
Th2	O
responses	O
[	O
24	O
,	O
25	O
].	O

SEA	O
is	O
recognized	O
and	O
internalized	O
by	O
human	B-OG
DCs	O
via	O
several	O
CLRs	B-GP
,	O
including	O
DC	B-GP
-	I-GP
specific	I-GP
ICAM	I-GP
-	I-GP
3	I-GP
-	I-GP
grabbing	I-GP
non	I-GP
-	I-GP
integrin	I-GP
(	O
DC	B-GP
-	I-GP
SIGN	I-GP
),	O
the	O
mannose	B-GP
receptor	I-GP
(	O
MR	B-GP
)	O
and	O
macrophage	B-GP
galactose	I-GP
-	I-GP
type	I-GP
lectin	I-GP
(	O
MGL	B-GP
),	O
important	O
receptors	O
for	O
internalization	O
of	O
glycosylated	O
antigens	O
and	O
intracellular	O
signaling	O
upon	O
binding	O
of	O
specific	O
glycans	O
[	O
17	O
,	O
26	O
,	O
27	O
,	O
28	O
].	O

Some	O
major	O
components	O
within	O
SEA	O
have	O
been	O
identified	O
that	O
bind	O
these	O
CLRs	B-GP
.	O

Omega	B-GP
-	I-GP
1	I-GP
and	O
IPSEα1	B-GP
,	O
which	O
both	O
contain	O
Galβ1	O
-	O
4	O
(	O
Fucα1	O
–	O
3	O
)	O
GlcNAc	O
(	O
Lewis	O
X	O
,	O
LeX	O
)	O
motifs	O
on	O
diantennary	O
N	O
-	O
glycans	O
[	O
29	O
,	O
30	O
],	O
interact	O
with	O
DCs	O
mainly	O
via	O
the	O
MR	B-GP
,	O
whereas	O
Kappa	O
-	O
5	O
interacts	O
with	O
all	O
three	O
CLRs	B-GP
[	O
31	O
].	O

It	O
has	O
been	O
shown	O
that	O
after	O
internalization	O
of	O
Omega	B-GP
-	I-GP
1	I-GP
in	O
the	O
DCs	O
by	O
the	O
MR	B-GP
,	O
its	O
RNase	B-GP
activity	O
contributes	O
to	O
an	O
anti	O
-	O
inflammatory	O
DC	O
phenotype	O
by	O
reducing	O
protein	O
synthesis	O
via	O
RNA	O
breakdown	O
[	O
32	O
].	O

Recent	O
data	O
show	O
that	O
SEA	O
contains	O
components	O
that	O
suppress	O
TLR	B-GP
-	O
induced	O
proinflammatory	B-GP
cytokine	I-GP
expression	O
via	O
DC	B-GP
-	I-GP
SIGN	I-GP
by	O
activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
family	O
member	O
Bcl3	B-GP
[	O
33	O
].	O

Thus	O
,	O
multiple	O
components	O
and	O
mechanisms	O
seem	O
to	O
play	O
a	O
role	O
in	O
immune	O
modulation	O
of	O
DCs	O
by	O
SEA	O
.	O

Using	O
total	O
SEA	O
we	O
here	O
provide	O
novel	O
mechanistic	O
evidence	O
that	O
SEA	O
glycans	O
contribute	O
to	O
the	O
induction	O
of	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
in	O
human	B-OG
DCs	O
.	O

Materials	O
and	O
Methods	O

Reagents	O

Human	B-OG
IL	B-GP
-	I-GP
4	I-GP
and	O
recombinant	O
human	B-OG
GM	B-GP
-	I-GP
CSF	I-GP
were	O
purchased	O
from	O
Immunotools	O
(	O
Germany	O
).	O
Escherichia	B-OG
coli	I-OG
LPS	O
(	O
strain	O
0111	O
:	O
B4	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
USA	O
).	O

For	O
flow	O
cytometric	O
analysis	O
PE	O
-	O
conjugated	O
mouse	B-OG
anti	O
-	O
human	B-OG
OX40L	B-GP
(	O
Ik	O
-	O
1	O
,	O
BD	O
Pharmingen	O
,	O
1	O
:	O
50	O
)	O
and	O
anti	O
-	O
human	B-OG
PD	B-GP
-	I-GP
L1	I-GP
(	O
eBioscience	O
,	O
MIH1	O
,	O
1	O
:	O
50	O
)	O
were	O
used	O
.	O

Monoclonal	O
anti	O
-	O
human	B-OG
DC	B-GP
-	I-GP
SIGN	I-GP
antibody	B-GP
was	O
purchased	O
from	O
R	O
&	O
D	O
systems	O
(	O
USA	O
).	O

In	O
addition	O
,	O
anti	O
-	O
human	B-OG
DC	B-GP
-	I-GP
SIGN	I-GP
antibody	B-GP
AZN	O
-	O
D1	O
was	O
used	O
[	O
34	O
].	O

Anti	O
-	O
human	B-OG
CD206	B-GP
(	O
MMR	O
)	O
antibody	B-GP
was	O
purchased	O
from	O
BD	O
Pharmingen	O
(	O
USA	O
,	O
clone	O
19	O
.	O
2	O
).	O

IgG2b	O
and	O
IgG1κ	B-GP
control	O
antibodies	B-GP
,	O
for	O
anti	O
-	O
DC	B-GP
-	I-GP
SIGN	I-GP
and	O
anti	O
-	O
MR	B-GP
antibodies	B-GP
respectively	O
,	O
were	O
purchased	O
from	O
BD	O
(	O
USA	O
).	O

Methyl	O
α	O
-	O
D	O
-	O
mannoside	O
(	O
MeMan	O
)	O
was	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
USA	O
).	O

Allyl	O
α	O
-	O
D	O
-	O
mannopyranoside	O
(	O
AllMan	O
)	O
was	O
synthesized	O
by	O
standard	O
Fischer	O
glycosylation	O
of	O
allyl	O
alcohol	O
using	O
D	O
-	O
mannose	O
and	O
acetyl	O
chloride	O
as	O
acidic	O
catalyst	O
as	O
described	O
[	O
35	O
].	O

Purity	O
of	O
the	O
product	O
was	O
confirmed	O
by	O
elemental	O
analysis	O
.	O

Monocyte	O
isolation	O
and	O
generation	O
of	O
human	B-OG
immature	O
dendritic	O
cells	O

Human	B-OG
monocytes	O
were	O
isolated	O
from	O
buffy	O
coats	O
of	O
healthy	O
donors	O
(	O
commercially	O
obtained	O
from	O
Sanquin	O
,	O
Amsterdam	O
,	O
the	O
Netherlands	O
)	O
or	O
fresh	O
blood	O
of	O
healthy	O
volunteers	O
,	O
who	O
gave	O
written	O
informed	O
consent	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
volunteers	O
by	O
a	O
qualified	O
technician	O
.	O

The	O
authors	O
had	O
no	O
interactions	O
with	O
the	O
volunteers	O
,	O
and	O
have	O
no	O
access	O
to	O
identifying	O
information	O
regarding	O
the	O
volunteers	O
.	O

The	O
Medical	O
Research	O
Involving	O
Human	B-OG
Subjects	O
Act	O
(	O
WMO	O
)	O
does	O
not	O
apply	O
to	O
this	O
study	O
and	O
an	O
official	O
approval	O
of	O
this	O
study	O
by	O
the	O
Medical	O
Ethics	O
Review	O
Committee	O
of	O
VU	O
University	O
Medical	O
Center	O
is	O
not	O
required	O
.	O

The	O
Medical	O
Ethics	O
Review	O
Committee	O
of	O
VU	O
University	O
Medical	O
Center	O
is	O
registered	O
with	O
the	O
US	O
Office	O
for	O
Human	B-OG
Research	O
Protections	O
(	O
OHRP	O
)	O
as	O
IRB00002991	O
.	O

The	O
FWA	O
number	O
assigned	O
to	O
VU	O
University	O
Medical	O
Center	O
is	O
FWA00017598	O
.	O

Monocytes	O
were	O
isolated	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
using	O
CD14	B-GP
microbeads	O
(	O
MACS	O
,	O
Miltenyi	O
Biotec	O
,	O
Germany	O
),	O
as	O
previously	O
described	O
[	O
36	O
]	O
and	O
differentiated	O
into	O
immature	O
DCs	O
in	O
the	O
presence	O
of	O
250	O
IU	O
/	O
ml	O
IL	B-GP
-	I-GP
4	I-GP
and	O
120	O
IU	O
/	O
ml	O
GM	B-GP
-	I-GP
CSF	I-GP
.	O

For	O
all	O
experiments	O
,	O
monocyte	O
derived	O
DCs	O
were	O
used	O
after	O
4	O
days	O
of	O
differentiation	O
.	O

In	O
all	O
DC	O
assays	O
LPS	O
was	O
used	O
at	O
a	O
final	O
concentration	O
of	O
10	O
ng	O
/	O
ml	O
.	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
was	O
used	O
at	O
a	O
final	O
concentration	O
of	O
40	O
μg	O
/	O
ml	O
unless	O
indicated	O
otherwise	O
.	O

For	O
all	O
SEA	O
and	O
LPS	O
co	O
-	O
incubations	O
,	O
SEA	O
was	O
added	O
15	O
minutes	O
prior	O
to	O
LPS	O
.	O

In	O
CLR	B-GP
blocking	O
experiments	O
,	O
blocking	O
compounds	O
and	O
antibodies	B-GP
were	O
added	O
to	O
the	O
DCs	O
for	O
2	O
hours	O
,	O
followed	O
by	O
4	O
hours	O
of	O
incubation	O
with	O
SEA	O
and	O
/	O
or	O
LPS	O
.	O

Denaturation	O
and	O
periodate	O
treatment	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O

Crude	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
was	O
kindly	O
made	O
available	O
by	O
Dr	O
.	O
Fred	O
Lewis	O
(	O
Biomedical	O
Research	O
Institute	O
,	O
Rockville	O
,	O
MD	O
,	O
USA	O
),	O
and	O
purified	O
as	O
described	O
previously	O
[	O
37	O
].	O

To	O
oxidize	O
glycan	O
moieties	O
,	O
SEA	O
was	O
treated	O
with	O
sodium	O
periodate	O
(	O
PI	O
)	O
as	O
previously	O
described	O
[	O
38	O
].	O

SEA	O
was	O
denatured	O
(	O
DN	O
)	O
by	O
incubation	O
for	O
20	O
min	O
.	O
at	O
80	O
°	O
C	O
,	O
then	O
immediately	O
cooled	O
on	O
ice	O
and	O
stored	O
at	O
-	O
20	O
°	O
C	O
until	O
use	O
.	O

Endotoxin	O
contamination	O
was	O
determined	O
in	O
all	O
samples	O
by	O
Limulus	O
Amoebocyte	O
Lysate	O
assay	O
(	O
Charles	O
River	O
Laboratories	O
,	O
Leiden	O
,	O
NL	O
).	O

Contamination	O
was	O
lower	O
than	O
1	O
ng	O
/	O
ml	O
endotoxin	O
for	O
all	O
preparations	O
.	O

The	O
SEA	O
preparation	O
used	O
does	O
not	O
contain	O
detectable	O
levels	O
of	O
LPS	O
in	O
functional	O
assays	O
in	O
DCs	O
and	O
TLR	B-GP
-	O
reporter	O
cells	O
,	O
tested	O
as	O
described	O
[	O
17	O
].	O

ELISA	O
and	O
DC	O
-	O
adhesion	O
using	O
immobilized	O
SEA	O

SEA	O
was	O
immobilized	O
in	O
wells	O
of	O
Nunc	O
Maxisorp	O
plates	O
(	O
Thermo	O
Scientific	O
)	O
in	O
all	O
experiments	O
.	O

Binding	O
of	O
the	O
human	B-OG
recombinant	O
hybrid	O
CLRs	B-GP
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
(	O
2	O
.	O
5	O
μg	O
/	O
ml	O
)	O
[	O
39	O
],	O
MGL	B-GP
-	O
Fc	O
(	O
0	O
.	O
5	O
μg	O
/	O
ml	O
)	O
[	O
28	O
]	O
and	O
murine	O
MR	B-GP
-	O
Fc	O
,	O
containing	O
the	O
carbohydrate	O
recognition	O
domains	O
CTLD4	O
-	O
7	O
(	O
1	O
μg	O
/	O
ml	O
,	O
a	O
kind	O
gift	O
from	O
L	O
.	O

Martinez	O
-	O
Pomares	O
)	O
to	O
SEA	O
(	O
5	O
μg	O
/	O
ml	O
),	O
was	O
detected	O
by	O
peroxidase	B-GP
-	O
conjugated	O
anti	O
-	O
human	B-OG
Fc	O
antibody	B-GP
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
,	O
USA	O
).	O

Adhesion	O
of	O
(	O
fluorescently	O
-	O
labelled	O
)	O
DCs	O
to	O
SEA	O
(	O
5	O
–	O
20	O
μg	O
/	O
ml	O
as	O
indicated	O
),	O
was	O
performed	O
essentially	O
as	O
previously	O
described	O
[	O
40	O
].	O

Fluorescence	O
was	O
measured	O
at	O
485	O
/	O
520	O
nm	O
with	O
a	O
FLUOstar	O
spectrofluorometer	O
(	O
BMG	O
Labtech	O
,	O
Ortenberg	O
,	O
Germany	O
).	O

Measurement	O
of	O
RNase	B-GP
activity	O

RNA	O
of	O
immature	O
DCs	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Untreated	O
,	O
DN	O
-	O
or	O
PI	O
-	O
treated	O
SEA	O
(	O
10	O
μg	O
/	O
ml	O
)	O
was	O
added	O
to	O
2	O
ng	O
of	O
RNA	O
each	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
1	O
hour	O
.	O

The	O
SEA	O
-	O
treated	O
RNA	O
samples	O
and	O
RNA	O
control	O
sample	O
were	O
loaded	O
on	O
an	O
RNase	B-GP
free	O
2	O
%	O
agarose	O
RNA	O
gel	O
and	O
electrophoresis	O
was	O
carried	O
out	O
to	O
separate	O
the	O
RNA	O
molecules	O
.	O

Buffers	O
and	O
gels	O
were	O
autoclaved	O
before	O
use	O
to	O
prevent	O
RNase	B-GP
contamination	O
.	O

Cytokine	B-GP
measurements	O

Culture	O
supernatants	O
were	O
harvested	O
after	O
DC	O
stimulation	O
at	O
indicated	O
time	O
points	O
and	O
frozen	O
at	O
-	O
20	O
°	O
C	O
until	O
further	O
analysis	O
.	O

TNFα	B-GP
was	O
routinely	O
measured	O
by	O
ELISA	O
using	O
the	O
CytoSet	O
ELISA	O
kit	O
(	O
Biosource	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

For	O
the	O
multiplex	O
bead	O
immunoassay	O
the	O
Human	B-OG
Inflammatory	O
5	O
-	O
plex	O
panel	O
(	O
Invitrogen	O
,	O
USA	O
)	O
was	O
supplemented	O
with	O
a	O
single	O
-	O
plex	O
kit	O
for	O
IL	B-GP
-	I-GP
12	I-GP
p70	O
(	O
Invitrogen	O
,	O
USA	O
).	O

The	O
assay	O
was	O
performed	O
according	O
to	O
Invitrogen	O
’	O
s	O
user	O
manual	O
‘	O
Human	B-OG
Inflammatory	O
5	O
-	O
Plex	O
Panel	O
’.	O

Samples	O
were	O
measured	O
by	O
Luminex	O
200	O
(	O
Bio	O
-	O
Rad	O
,	O
USA	O
)	O
and	O
data	O
analysis	O
was	O
performed	O
using	O
Bio	O
-	O
plex	O
Manager	O
6	O
.	O
0	O
software	O
.	O

The	O
TGF	B-GP
-	I-GP
β1	I-GP
ELISA	O
(	O
Promega	O
,	O
G7591	O
)	O
was	O
done	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Flow	O
cytometry	O

For	O
the	O
determination	O
of	O
PD	B-GP
-	I-GP
L1	I-GP
expression	O
,	O
buffycoat	O
-	O
derived	O
DCs	O
were	O
stimulated	O
with	O
SEA	O
for	O
24h	O
.	O

To	O
measure	O
OX40L	B-GP
,	O
DCs	O
were	O
differentiated	O
from	O
fresh	O
blood	O
-	O
isolated	O
monocytes	O
as	O
described	O
.	O

Expression	O
of	O
OX40L	B-GP
on	O
the	O
cell	O
surface	O
was	O
determined	O
after	O
a	O
48h	O
co	O
-	O
incubation	O
of	O
the	O
DCs	O
with	O
SEA	O
antigens	O
and	O
LPS	O
.	O

Cell	O
staining	O
was	O
analysed	O
by	O
flow	O
cytometry	O
using	O
a	O
BD	O
FACSScan	O
(	O
Becton	O
Dickson	O
,	O
USA	O
).	O

Data	O
were	O
analyzed	O
using	O
CellQuest	O
Pro	O
software	O
(	O
version	O
3	O
.	O
3	O
,	O
Becton	O
Dickinson	O
,	O
USA	O
).	O

Mixed	O
Lymphocyte	O
Reaction	O

Immature	O
DCs	O
were	O
stimulated	O
for	O
24	O
hours	O
.	O

Subsequently	O
,	O
naïve	O
CD4	B-GP
+	O
T	O
cells	O
were	O
isolated	O
using	O
a	O
negative	O
selection	O
naïve	O
CD4	B-GP
+	O
T	O
cell	O
isolation	O
kit	O
(	O
Miltenyi	O
Biotec	O
,	O
Germany	O
).	O

DCs	O
were	O
counted	O
and	O
cocultured	O
with	O
immature	O
CD4	B-GP
+	O
T	O
cells	O
for	O
6	O
days	O
in	O
triplicate	O
for	O
each	O
donor	O
.	O

On	O
day	O
5	O
,	O
tritium	O
thymidine	O
(	O
0	O
.	O
02	O
mCi	O
/	O
ml	O
)	O
was	O
added	O
.	O

Tritium	O
thymidine	O
incorporation	O
was	O
determined	O
using	O
the	O
Unifilter	O
-	O
96	O
harvester	O
(	O
PerkinElmer	O
,	O
USA	O
).	O

Quantitative	O
RT	O
-	O
PCR	O

DCs	O
were	O
harvested	O
at	O
time	O
points	O
indicated	O
,	O
and	O
snap	O
-	O
frozen	O
at	O
-	O
80	O
°	O
C	O
.	O
mRNA	O
was	O
isolated	O
using	O
the	O
mRNA	O
Capture	O
kit	O
(	O
Roche	O
,	O
Switzerland	O
),	O
and	O
subsequently	O
transcribed	O
into	O
cDNA	O
using	O
the	O
Reverse	O
Transcription	O
System	O
kit	O
(	O
Promega	O
,	O
USA	O
),	O
as	O
described	O
previously	O
[	O
41	O
].	O

PCR	O
reactions	O
were	O
performed	O
with	O
the	O
SYBR	O
Green	O
method	O
as	O
described	O
previously	O
[	O
42	O
].	O

Oligonucleotides	O
were	O
designed	O
using	O
Primer	O
Express	O
2	O
.	O
0	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
)	O
computer	O
software	O
.	O

All	O
oligonucleotides	O
were	O
synthesized	O
by	O
Ocimum	O
(	O
Ocimum	O
Biosolutions	O
,	O
India	O
).	O

Primer	O
sequences	O
were	O
designed	O
as	O
shown	O
in	O
Table	O
1	O
.	O

Oligonucleotide	O
primers	O
for	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Gene	O

Forward	O

Reverse	O

SOCS1	B-GP

TGAACTCGCACCTCCTACCTCT	O

CAACCCCTGGTTTGTGCAA	O

SOCS2	B-GP

TCTCTGCAGCATCTCTGTAGGC	O

GATGGCACCGGTACATTTGTT	O

SOCS3	B-GP

TTTCTGATCCGCGACAGCT	O

TGACGCTGAGCGTGAAGAAGT	O

SHP1	B-GP

ACTCCGTACCTTACAGGTCTCCC	O

GATCTCCCGAATCAGGTCTCC	O

SHP2	B-GP

GAGAGAAAGGTGTTGACTGCGATA	O

CCTCTGAGACCGCACCATCT	O

PD	B-GP
-	I-GP
L1	I-GP

ACAGCTGAATTGGTCATCCCA	O

TTCATTTGGAGGATGTGCCA	O

TGF	B-GP
-	I-GP
β	I-GP

ACTATTGCTTCAGCTCCACGGA	O

AGTCAATGTACAGCTGCCGCA	O

GAPDH	B-GP

CCATGTTCGTCATGGGTGTG	O

GGTGCTAAGCAGTTGGTGGTG	O

SOCS	B-GP
,	O
Suppressor	B-GP
of	I-GP
Cytokine	I-GP
Signalling	I-GP
;	O
SHP	B-GP
,	O
SH2	B-GP
-	I-GP
containing	I-GP
protein	I-GP
tyrosine	I-GP
Phosphatase	I-GP
;	O
PD	B-GP
-	I-GP
L1	I-GP
,	O
Programmed	B-GP
Death	I-GP
Ligand	I-GP
1	I-GP
;	O
TGF	B-GP
,	O
Transforming	B-GP
Growth	I-GP
Factor	I-GP
;	O
GAPDH	B-GP
,	O
Glyceraldehyde	B-GP
3	I-GP
-	I-GP
Phosphatase	I-GP
Dehydrogenase	I-GP

SDS	O
-	O
PAGE	O
and	O
Western	O
Blotting	O

DC	O
samples	O
were	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotting	O
using	O
rabbit	B-OG
-	O
anti	O
-	O
human	B-OG
SOCS1	B-GP
(	O
Cell	O
Signaling	O
,	O
3950	O
,	O
1	O
:	O
750	O
),	O
rabbit	B-OG
-	O
anti	O
-	O
human	B-OG
SOCS2	B-GP
(	O
Cell	O
Signaling	O
,	O
2779	O
,	O
1	O
:	O
500	O
),	O
goat	B-OG
-	O
anti	O
-	O
rabbit	B-OG
-	O
HRP	B-GP
(	O
Dako	O
,	O
P0448	O
1	O
:	O
2000	O
),	O
mouse	B-OG
-	O
anti	O
-	O
human	B-OG
GAPDH	B-GP
(	O
9484	O
Abcam	O
,	O
UK	O
,	O
1	O
:	O
1000	O
),	O
rabbit	B-OG
-	O
anti	O
-	O
mouse	B-OG
-	O
HRP	B-GP
(	O
P0161	O
,	O
Dako	O
,	O
P0161	O
,	O
1	O
:	O
2000	O
),	O
rabbit	B-OG
-	O
anti	O
-	O
human	B-OG
SHP1	B-GP
(	O
GeneTex	O
,	O
102865	O
,	O
1	O
:	O
500	O
)	O
rabbit	B-OG
-	O
anti	O
-	O
human	B-OG
SHP2	B-GP
(	O
Santa	O
Cruz	O
,	O
C	O
-	O
18	O
,	O
1	O
:	O
250	O
)	O
and	O
goat	B-OG
-	O
anti	O
-	O
human	B-OG
Actin	B-GP
(	O
Santa	O
Cruz	O
,	O
I	O
-	O
19	O
,	O
1	O
:	O
2000	O
).	O

Proteins	O
were	O
detected	O
using	O
SuperSignal	O
West	O
Pico	O
Chemiluminescent	O
Substrate	O
(	O
Thermo	O
Scientific	O
,	O
USA	O
),	O
in	O
an	O
EpiChemi	O
II	O
Darkroom	O
(	O
UPV	O
Laboratory	O
Products	O
).	O

Bands	O
were	O
quantified	O
using	O
Labworks	O
4	O
.	O
0	O
image	O
acquisition	O
and	O
analysis	O
software	O
.	O

DN	O
or	O
PI	O
-	O
treated	O
and	O
untreated	O
SEA	O
(	O
10	O
μg	O
/	O
ml	O
)	O
were	O
analysed	O
by	O
gel	O
electrophoresis	O
and	O
silver	O
staining	O
according	O
to	O
the	O
manufacturers	O
protocol	O
(	O
Bio	O
-	O
Rad	O
).	O

Statistical	O
analysis	O

Results	O
are	O
expressed	O
as	O
the	O
mean	O
plus	O
or	O
minus	O
SEM	O
.	O

To	O
correct	O
for	O
the	O
large	O
donor	O
variation	O
in	O
cytokine	B-GP
production	O
,	O
the	O
level	O
of	O
cytokine	B-GP
secretion	O
induced	O
upon	O
LPS	O
-	O
stimulation	O
was	O
set	O
at	O
100	O
%	O
for	O
each	O
donor	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
20	O
.	O
0	O
software	O
(	O
IBM	O
,	O
USA	O
).	O

For	O
paired	O
comparisons	O
of	O
two	O
groups	O
,	O
a	O
paired	O
sample	O
T	O
-	O
test	O
was	O
performed	O
.	O

For	O
other	O
parametric	O
data	O
,	O
a	O
one	O
-	O
way	O
ANOVA	O
was	O
performed	O
followed	O
by	O
Dunnett	O
’	O
s	O
multiple	O
comparisons	O
test	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Results	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
glycans	O
are	O
involved	O
in	O
modulation	O
of	O
DC	O
phenotype	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
has	O
previously	O
been	O
shown	O
to	O
modulate	O
DC	O
maturation	O
,	O
including	O
the	O
suppression	O
of	O
TLR	B-GP
-	O
induced	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
production	O
,	O
in	O
a	O
concentration	O
dependent	O
manner	O
[	O
17	O
].	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
SEA	O
acts	O
on	O
human	B-OG
DCs	O
are	O
incompletely	O
understood	O
.	O

To	O
discriminate	O
between	O
possible	O
glycan	O
-	O
and	O
RNase	B-GP
-	O
mediated	O
effects	O
of	O
the	O
helminth	B-OG
antigens	O
,	O
SEA	O
was	O
either	O
heat	O
-	O
denatured	O
(	O
DN	O
)	O
to	O
abolish	O
RNase	B-GP
activity	O
,	O
or	O
periodate	O
(	O
PI	O
)	O
treated	O
,	O
to	O
oxidize	O
glycan	O
structures	O
[	O
43	O
].	O

To	O
confirm	O
the	O
effectiveness	O
of	O
PI	O
treatment	O
,	O
the	O
binding	O
capacity	O
of	O
different	O
CLRs	B-GP
to	O
the	O
treated	O
SEA	O
preparations	O
was	O
measured	O
.	O

PI	O
treatment	O
caused	O
loss	O
of	O
binding	O
by	O
the	O
recombinant	O
CLR	B-GP
-	O
Fc	O
hybrids	O
MGL	B-GP
-	O
Fc	O
,	O
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
and	O
MR	B-GP
-	O
Fc	O
to	O
SEA	O
(	O
Fig	O
1A	O
),	O
indicating	O
that	O
the	O
glycan	O
ligands	O
for	O
these	O
CLRs	B-GP
were	O
destroyed	O
by	O
PI	O
treatment	O
.	O

By	O
contrast	O
,	O
heat	O
treatment	O
(	O
DN	O
)	O
of	O
SEA	O
did	O
not	O
affect	O
lectin	B-GP
binding	O
,	O
indicating	O
the	O
presence	O
of	O
intact	O
glycan	O
ligands	O
on	O
the	O
heat	O
-	O
treated	O
antigens	O
.	O

Heat	O
treatment	O
did	O
,	O
however	O
,	O
abolish	O
the	O
capacity	O
of	O
SEA	O
to	O
degrade	O
RNA	O
(	O
Fig	O
1B	O
),	O
indicating	O
that	O
RNase	B-GP
activity	O
was	O
destroyed	O
,	O
whereas	O
PI	O
treatment	O
did	O
not	O
destroy	O
the	O
RNase	B-GP
activity	O
within	O
SEA	O
.	O

The	O
mild	O
DN	O
and	O
PI	O
treatments	O
did	O
not	O
result	O
in	O
precipitation	O
or	O
loss	O
of	O
SEA	O
proteins	O
,	O
as	O
indicated	O
by	O
SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
final	O
sample	O
(	O
Fig	O
1C	O
).	O

Treatments	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
with	O
periodate	O
(	O
PI	O
)	O
or	O
heat	O
(	O
DN	O
)	O
results	O
in	O
modified	O
glycan	O
structures	O
,	O
or	O
inactivation	O
of	O
RNase	B-GP
activity	O
,	O
respectively	O
.	O

A	O
.	O

Binding	O
of	O
IgG	B-GP
-	O
Fc	O
hybrid	O
molecules	O
of	O
the	O
C	B-GP
-	I-GP
type	I-GP
lectin	I-GP
receptors	I-GP
DC	B-GP
-	I-GP
SIGN	I-GP
,	O
MGL	B-GP
and	O
MR	B-GP
to	O
untreated	O
(	O
U	O
)	O
SEA	O
,	O
SEA	O
treated	O
with	O
10	O
mM	O
periodate	O
(	O
PI	O
),	O
or	O
heated	O
at	O
80	O
°	O
C	O
for	O
20	O
min	O
(	O
DN	O
)	O
(	O
coated	O
at	O
5	O
μg	O
/	O
ml	O
)	O
was	O
assessed	O
by	O
ELISA	O
.	O

In	O
addition	O
,	O
binding	O
to	O
SEA	O
was	O
evaluated	O
in	O
the	O
presence	O
of	O
EDTA	O
(	O
5	O
mM	O
),	O
which	O
prevents	O
CLR	B-GP
binding	O
by	O
removing	O
calcium	O
.	O
B	O
.	O

RNase	B-GP
activity	O
of	O
the	O
differentially	O
treated	O
SEA	O
was	O
assessed	O
using	O
total	O
RNA	O
isolated	O
from	O
human	B-OG
dendritic	O
cells	O
.	O

All	O
SEA	O
samples	O
were	O
incubated	O
with	O
RNA	O
for	O
1h	O
at	O
37	O
°	O
C	O
and	O
subsequently	O
agarose	O
gel	O
electrophoresis	O
was	O
performed	O
under	O
RNase	B-GP
-	O
free	O
conditions	O
to	O
visualize	O
degradation	O
of	O
the	O
RNA	O
.	O

The	O
position	O
of	O
the	O
28S	O
and	O
18S	O
ribosomal	O
units	O
in	O
the	O
gel	O
are	O
indicated	O
by	O
arrows	O
.	O
C	O
.	O

Silver	O
staining	O
of	O
an	O
SDS	O
-	O
PAGE	O
protein	O
gel	O
loaded	O
with	O
SEA	O
U	O
,	O
DN	O
and	O
PI	O
(	O
10	O
μg	O
/	O
ml	O
).	O

The	O
position	O
of	O
10	O
and	O
250kD	O
molecular	O
weight	O
markers	O
on	O
the	O
gel	O
are	O
indicated	O
by	O
arrows	O
.	O

The	O
data	O
shown	O
are	O
typical	O
examples	O
out	O
of	O
3	O
independent	O
experiments	O
.	O

After	O
establishing	O
the	O
efficacy	O
of	O
both	O
heat	O
and	O
periodate	O
treatments	O
,	O
human	B-OG
DCs	O
were	O
pulsed	O
with	O
treated	O
and	O
untreated	O
SEA	O
in	O
the	O
presence	O
of	O
LPS	O
,	O
and	O
their	O
immunomodulatory	O
capacities	O
were	O
analysed	O
.	O

The	O
results	O
in	O
Fig	O
2	O
establish	O
that	O
secretion	O
of	O
the	O
LPS	O
-	O
induced	O
cytokines	B-GP
tumor	B-GP
necrosis	I-GP
factor	I-GP
α	I-GP
(	O
TNFα	B-GP
),	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
12p70	I-GP
by	O
DCs	O
was	O
suppressed	O
by	O
SEA	O
and	O
show	O
that	O
this	O
suppression	O
was	O
not	O
significantly	O
affected	O
by	O
heat	O
-	O
treatment	O
of	O
the	O
antigens	O
,	O
indicating	O
that	O
RNase	B-GP
activity	O
does	O
not	O
significantly	O
contribute	O
to	O
the	O
observed	O
effects	O
.	O

In	O
contrast	O
,	O
PI	O
treatment	O
of	O
SEA	O
did	O
abolish	O
its	O
ability	O
to	O
suppress	O
these	O
cytokines	B-GP
(	O
Fig	O
2A	O
–	O
2C	O
).	O

In	O
addition	O
,	O
CD4	B-GP
+	O
T	O
cell	O
proliferation	O
,	O
as	O
measured	O
by	O
an	O
MLR	O
,	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
either	O
untreated	O
or	O
heat	O
-	O
treated	O
SEA	O
(	O
Fig	O
2E	O
),	O
but	O
not	O
by	O
PI	O
-	O
treated	O
SEA	O
.	O

The	O
enhanced	O
OX40L	B-GP
expression	O
induced	O
by	O
SEA	O
in	O
the	O
presence	O
of	O
LPS	O
was	O
inhibited	O
by	O
either	O
heat	O
-	O
treatment	O
or	O
PI	O
-	O
treatment	O
(	O
Fig	O
2D	O
),	O
indicating	O
the	O
importance	O
of	O
both	O
an	O
intact	O
glycan	O
and	O
protein	O
structure	O
here	O
.	O

These	O
data	O
indicate	O
that	O
SEA	O
-	O
glycans	O
significantly	O
contribute	O
to	O
the	O
modulation	O
of	O
DC	O
function	O
.	O

The	O
ability	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
to	O
suppress	O
LPS	O
-	O
induced	O
human	B-OG
dendritic	O
cell	O
(	O
DC	O
)	O
activation	O
and	O
OX40L	B-GP
expression	O
on	O
DCs	O
is	O
reduced	O
after	O
periodate	O
treatment	O
of	O
SEA	O
.	O

DCs	O
were	O
incubated	O
with	O
LPS	O
,	O
with	O
or	O
without	O
either	O
untreated	O
(	O
U	O
),	O
heat	O
treated	O
(	O
DN	O
)	O
or	O
periodate	O
(	O
PI	O
)	O
treated	O
SEA	O
(	O
40	O
μg	O
/	O
ml	O
)	O
for	O
24h	O
.	O

In	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
respectively	O
is	O
shown	O
the	O
secretion	O
of	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
12	I-GP
,	O
which	O
were	O
determined	O
in	O
the	O
supernatant	O
by	O
Luminex	O
multiplex	O
bead	O
analysis	O
or	O
ELISA	O
.	O

Experiments	O
using	O
SEA	O
alone	O
did	O
not	O
affect	O
cytokine	B-GP
production	O
of	O
DCs	O
(	O
controls	O
,	O
not	O
shown	O
).	O

Cytokine	B-GP
secretion	O
by	O
LPS	O
alone	O
was	O
set	O
at	O
100	O
%	O
separately	O
for	O
each	O
donor	O
and	O
varied	O
for	O
TNFα	B-GP
from	O
100	O
–	O
550	O
ng	O
/	O
ml	O
,	O
for	O
IL	B-GP
-	I-GP
6	I-GP
from	O
4	O
–	O
20	O
ng	O
/	O
ml	O
and	O
for	O
IL	B-GP
-	I-GP
12	I-GP
from	O
50	O
–	O
200	O
ng	O
/	O
ml	O
,	O
dependent	O
on	O
the	O
blood	O
donor	O
used	O
.	O
D	O
.	O

The	O
expression	O
of	O
OX40L	B-GP
on	O
the	O
DC	O
surface	O
was	O
assessed	O
by	O
flow	O
cytometry	O
after	O
48h	O
.	O
E	O
.	O

A	O
mixed	O
lymphocyte	O
reaction	O
was	O
done	O
by	O
priming	O
the	O
DCs	O
for	O
24h	O
with	O
LPS	O
in	O
the	O
presence	O
or	O
absence	O
of	O
SEA	O
,	O
followed	O
by	O
coculture	O
of	O
the	O
primed	O
DCs	O
with	O
heterologous	O
naïve	O
CD4	B-GP
+	O
T	O
cells	O
for	O
6	O
days	O
.	O

Tritiated	O
thymidine	O
incorporation	O
was	O
determined	O
during	O
the	O
final	O
24h	O
of	O
incubation	O
.	O

Results	O
are	O
expressed	O
as	O
mean	O
plus	O
or	O
minus	O
SEM	O
and	O
reflect	O
the	O
mean	O
of	O
experiments	O
performed	O
in	O
duplicate	O
with	O
DCs	O
from	O
8	O
(	O
A	O
),	O
4	O
(	O
B	O
,	O
C	O
,	O
E	O
)	O
or	O
3	O
(	O
D	O
)	O
separate	O
donors	O
.	O

Significance	O
is	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
vs	O
untreated	O
(	O
A	O
-	O
C	O
,	O
E	O
)	O
or	O
LPS	O
alone	O
(	O
D	O
).	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
induces	O
expression	O
of	O
different	O
immunomodulators	O
in	O
human	B-OG
DCs	O

To	O
provide	O
insights	O
into	O
the	O
pathways	O
used	O
by	O
SEA	O
for	O
human	B-OG
DC	O
modulation	O
,	O
mRNA	O
levels	O
of	O
known	O
negative	O
regulators	O
of	O
the	O
TLR4	B-GP
signalling	O
pathway	O
were	O
determined	O
[	O
44	O
,	O
45	O
].	O

DCs	O
were	O
incubated	O
with	O
SEA	O
in	O
the	O
presence	O
and	O
absence	O
of	O
LPS	O
.	O

Our	O
data	O
show	O
that	O
SEA	O
significantly	O
induced	O
mRNA	O
levels	O
of	O
SOCS1	B-GP
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
,	O
with	O
a	O
further	O
enhanced	O
response	O
upon	O
costimulation	O
with	O
LPS	O
(	O
Fig	O
3A	O
).	O

In	O
addition	O
,	O
SEA	O
induced	O
SOCS2	B-GP
mRNA	O
levels	O
(	O
Fig	O
3B	O
)	O
and	O
SOCS3	B-GP
levels	O
(	O
Fig	O
3E	O
).	O

It	O
has	O
previously	O
been	O
shown	O
that	O
SEA	O
-	O
stimulated	O
DCs	O
induce	O
SOCS3	B-GP
protein	O
levels	O
[	O
46	O
].	O

Determination	O
of	O
SOCS1	B-GP
and	O
SOCS2	B-GP
protein	O
levels	O
by	O
western	O
blotting	O
showed	O
that	O
SOCS1	B-GP
levels	O
were	O
increased	O
at	O
1h	O
after	O
DC	O
stimulation	O
with	O
SEA	O
and	O
remained	O
increased	O
for	O
several	O
hours	O
(	O
Fig	O
3C	O
),	O
whereas	O
induction	O
of	O
SOCS2	B-GP
protein	O
levels	O
was	O
not	O
significant	O
(	O
Fig	O
3D	O
).	O

SEA	O
treatment	O
of	O
DCs	O
also	O
enhanced	O
the	O
expression	O
of	O
SHP1	B-GP
and	O
SHP2	B-GP
mRNA	O
levels	O
(	O
Fig	O
3F	O
and	O
3G	O
).	O

Determination	O
of	O
SEA	O
-	O
induced	O
SHP	B-GP
protein	O
levels	O
showed	O
that	O
although	O
the	O
protein	O
levels	O
of	O
SHP2	B-GP
remained	O
unaltered	O
upon	O
DC	O
stimulation	O
with	O
SEA	O
,	O
expression	O
of	O
SHP1	B-GP
protein	O
was	O
enhanced	O
after	O
4h	O
(	O
Fig	O
3H	O
).	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
induces	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
Suppressor	B-GP
of	I-GP
Cytokine	I-GP
Signaling	I-GP
1	I-GP
(	O
SOCS1	B-GP
),	O
SH2	B-GP
-	I-GP
containing	I-GP
protein	I-GP
tyrosine	I-GP
phosphatase	I-GP
1	I-GP
(	O
SHP1	B-GP
),	O
Programmed	B-GP
Death	I-GP
Ligand	I-GP
1	I-GP
(	O
PD	B-GP
-	I-GP
L1	I-GP
)	O
and	O
transforming	B-GP
growth	I-GP
factor	I-GP
β	I-GP
(	O
TGF	B-GP
-	I-GP
β	I-GP
),	O
in	O
human	B-OG
dendritic	O
cells	O
(	O
DCs	O
).	O

DCs	O
were	O
cultured	O
with	O
SEA	O
(	O
40	O
μg	O
/	O
ml	O
)	O
and	O
/	O
or	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
the	O
indicated	O
time	O
periods	O
.	O

mRNA	O
levels	O
were	O
detected	O
using	O
quantitative	O
real	O
time	O
PCR	O
with	O
GAPDH	B-GP
as	O
a	O
reference	O
gene	O
,	O
whereas	O
protein	O
levels	O
were	O
determined	O
by	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
,	O
using	O
specific	O
antibodies	B-GP
and	O
reference	O
gene	O
antibodies	B-GP
on	O
the	O
same	O
blots	O
.	O

Quantification	O
of	O
protein	O
was	O
performed	O
by	O
density	O
scanning	O
.	O

In	O
A	O
,	O
B	O
,	O
and	O
E	O
,	O
respectively	O
,	O
the	O
mRNA	O
levels	O
of	O
SEA	O
-	O
induced	O
SOCS1	B-GP
,	O
SOCS2	B-GP
,	O
and	O
SOCS3	B-GP
are	O
shown	O
,	O
whereas	O
the	O
protein	O
levels	O
of	O
SOCS1	B-GP
and	O
SOCS2	B-GP
are	O
shown	O
in	O
C	O
and	O
D	O
,	O
respectively	O
.	O

In	O
F	O
and	O
G	O
,	O
respectively	O
,	O
the	O
mRNA	O
levels	O
of	O
SEA	O
-	O
induced	O
SHP1	B-GP
and	O
SHP2	B-GP
are	O
shown	O
,	O
and	O
their	O
protein	O
levels	O
are	O
shown	O
in	O
H	O
.	O

The	O
mRNA	O
levels	O
of	O
PDL	B-GP
-	I-GP
1	I-GP
and	O
TGF	B-GP
-	I-GP
β	I-GP
are	O
shown	O
in	O
J	O
and	O
M	O
,	O
respectively	O
.	O

Protein	O
levels	O
of	O
PD	B-GP
-	I-GP
L1	I-GP
were	O
determined	O
by	O
flow	O
cytometry	O
(	O
K	O
)	O
and	O
TGF	B-GP
-	I-GP
β1	I-GP
protein	O
levels	O
were	O
determined	O
by	O
ELISA	O
(	O
N	O
).	O
L	O
shows	O
a	O
typical	O
example	O
of	O
a	O
FACS	O
plot	O
from	O
one	O
of	O
the	O
experiments	O
shown	O
in	O
K	O
.	O

Results	O
are	O
shown	O
as	O
mean	O
fold	O
difference	O
from	O
unstimulated	O
DCs	O
,	O
plus	O
or	O
minus	O
SEM	O
.	O

Results	O
are	O
derived	O
from	O
experiments	O
performed	O
in	O
duplicate	O
using	O
DCs	O
derived	O
from	O
7	O
(	O
A	O
),	O
4	O
(	O
B	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
H	O
,	O
J	O
,	O
N	O
)	O
or	O
3	O
(	O
C	O
,	O
F	O
,	O
M	O
,	O
K	O
)	O
different	O
donors	O
.	O

Significance	O
is	O
indicated	O
versus	O
unstimulated	O
DCs	O
as	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Furthermore	O
,	O
DC	O
stimulation	O
with	O
SEA	O
resulted	O
in	O
the	O
induced	O
expression	O
of	O
the	O
surface	O
marker	O
PD	B-GP
-	I-GP
L1	I-GP
and	O
the	O
cytokine	B-GP
TGF	B-GP
-	I-GP
β	I-GP
both	O
on	O
the	O
mRNA	O
level	O
(	O
Fig	O
3J	O
and	O
3M	O
)	O
and	O
the	O
protein	O
level	O
(	O
Fig	O
3K	O
,	O
3L	O
and	O
3N	O
).	O

SOCS1	B-GP
and	O
SHP1	B-GP
are	O
not	O
induced	O
upon	O
contact	O
of	O
DCs	O
with	O
immobilized	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O

In	O
regard	O
to	O
the	O
mechanism	O
by	O
which	O
SEA	O
negatively	O
regulates	O
TLR4	B-GP
signaling	O
,	O
we	O
hypothesized	O
that	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
has	O
to	O
be	O
recognized	O
and	O
internalized	O
by	O
lectin	B-GP
-	I-GP
receptors	I-GP
present	O
on	O
DCs	O
to	O
suppress	O
the	O
cytokine	B-GP
production	O
from	O
LPS	O
-	O
activated	O
DCs	O
,	O
and	O
/	O
or	O
to	O
enhance	O
expression	O
levels	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
.	O

To	O
test	O
this	O
possibility	O
,	O
SEA	O
was	O
presented	O
to	O
DCs	O
either	O
soluble	O
in	O
the	O
culture	O
medium	O
,	O
or	O
immobilized	O
to	O
a	O
plate	O
to	O
prevent	O
internalization	O
.	O

Immobilization	O
of	O
SEA	O
resulted	O
in	O
loss	O
of	O
its	O
capacity	O
to	O
suppress	O
the	O
LPS	O
-	O
induced	O
production	O
of	O
TNFα	B-GP
and	O
possibly	O
IL	B-GP
-	I-GP
12p70	I-GP
in	O
DCs	O
,	O
whereas	O
suppression	O
of	O
IL	B-GP
-	I-GP
6	I-GP
production	O
remained	O
unaltered	O
(	O
Fig	O
4A	O
–	O
4C	O
).	O

In	O
addition	O
,	O
immobilization	O
caused	O
a	O
complete	O
loss	O
of	O
the	O
expression	O
of	O
both	O
SOCS1	B-GP
and	O
SHP1	B-GP
(	O
Fig	O
4D	O
and	O
4E	O
).	O

These	O
data	O
show	O
that	O
a	O
complete	O
loss	O
of	O
induction	O
of	O
both	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
is	O
associated	O
with	O
a	O
loss	O
of	O
suppression	O
of	O
TNFα	B-GP
,	O
but	O
not	O
IL	B-GP
-	I-GP
6	I-GP
production	O
,	O
indicating	O
a	O
difference	O
between	O
the	O
regulation	O
of	O
expression	O
or	O
secretion	O
of	O
these	O
cytokines	B-GP
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
uptake	O
of	O
SEA	O
by	O
DCs	O
is	O
required	O
for	O
their	O
ability	O
to	O
suppress	O
LPS	O
-	O
induced	O
TNFα	B-GP
production	O
and	O
to	O
enhance	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
.	O

The	O
ability	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
to	O
induce	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
and	O
to	O
suppress	O
TNFα	B-GP
production	O
in	O
human	B-OG
dendritic	O
cells	O
(	O
DCs	O
)	O
is	O
lost	O
by	O
immobilization	O
of	O
SEA	O
.	O

DCs	O
were	O
incubated	O
with	O
20	O
μg	O
/	O
ml	O
soluble	O
SEA	O
(	O
S	O
)	O
or	O
immobilized	O
SEA	O
(	O
I	O
)	O
with	O
or	O
without	O
LPS	O
.	O

SEA	O
was	O
coated	O
to	O
wells	O
of	O
an	O
ELISA	O
plate	O
,	O
and	O
the	O
plate	O
was	O
washed	O
before	O
DCs	O
were	O
added	O
,	O
A	O
-	O
C	O
The	O
production	O
of	O
the	O
cytokines	B-GP
TNFα	B-GP
(	O
A	O
),	O
IL	B-GP
-	I-GP
12p70	I-GP
(	O
B	O
)	O
and	O
IL	B-GP
-	I-GP
6	I-GP
(	O
C	O
)	O
was	O
determined	O
in	O
the	O
DC	O
supernatants	O
after	O
4h	O
(	O
IL	B-GP
-	I-GP
6	I-GP
and	O
TNFα	B-GP
)	O
or	O
24h	O
(	O
IL	B-GP
-	I-GP
12p70	I-GP
).	O

The	O
cytokine	B-GP
production	O
of	O
LPS	O
-	O
activated	O
DCs	O
was	O
set	O
at	O
100	O
%	O
in	O
each	O
experiment	O
and	O
varied	O
for	O
TNFα	B-GP
from	O
40	O
–	O
200	O
ng	O
/	O
ml	O
,	O
for	O
IL	B-GP
-	I-GP
6	I-GP
from	O
2	O
–	O
10	O
ng	O
/	O
ml	O
and	O
for	O
IL	B-GP
-	I-GP
12	I-GP
from	O
50	O
–	O
200	O
ng	O
/	O
ml	O
,	O
dependent	O
on	O
the	O
blood	O
donor	O
used	O
.	O
D	O
-	O
E	O
Relative	O
mRNA	O
levels	O
of	O
SOCS1	B-GP
(	O
D	O
)	O
and	O
SHP1	B-GP
(	O
E	O
)	O
were	O
determined	O
in	O
the	O
cells	O
after	O
4h	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
GAPDH	B-GP
as	O
reference	O
gene	O
.	O

Results	O
are	O
shown	O
from	O
experiments	O
performed	O
in	O
duplicate	O
using	O
DCs	O
derived	O
from	O
5	O
(	O
A	O
),	O
4	O
(	O
B	O
,	O
C	O
)	O
or	O
3	O
(	O
D	O
,	O
E	O
)	O
different	O
blood	O
donors	O
,	O
and	O
are	O
displayed	O
as	O
the	O
mean	O
plus	O
or	O
minus	O
SEM	O
.	O

Significance	O
is	O
indicated	O
versus	O
LPS	O
-	O
stimulated	O
DCs	O
(	O
A	O
-	O
C	O
)	O
or	O
SEA	O
-	O
stimulated	O
DCs	O
(	O
D	O
-	O
E	O
)	O
as	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
,	O
0	O
.	O
001	O
.	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
-	O
induced	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
is	O
reduced	O
by	O
blocking	O
its	O
interaction	O
with	O
the	O
MR	B-GP

SEA	O
has	O
previously	O
been	O
shown	O
to	O
be	O
internalized	O
via	O
the	O
glycan	O
binding	O
CLRs	B-GP
DC	B-GP
-	I-GP
SIGN	I-GP
,	O
MGL	B-GP
and	O
MR	B-GP
[	O
17	O
].	O

Thus	O
,	O
we	O
hypothesized	O
that	O
induction	O
of	O
SOCS1	B-GP
and	O
/	O
or	O
SHP1	B-GP
may	O
depend	O
on	O
internalization	O
of	O
SEA	O
by	O
DCs	O
via	O
interaction	O
of	O
SEA	O
-	O
associated	O
glycans	O
with	O
one	O
or	O
more	O
of	O
these	O
CLRs	B-GP
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
SOCS1	B-GP
and	O
SHP1	B-GP
mRNA	O
levels	O
were	O
determined	O
in	O
DCs	O
pulsed	O
with	O
either	O
PI	O
-	O
treated	O
or	O
untreated	O
SEA	O
.	O

Interestingly	O
,	O
PI	O
treatment	O
of	O
SEA	O
resulted	O
in	O
a	O
reduced	O
mRNA	O
expression	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
(	O
Fig	O
5A	O
),	O
indicating	O
that	O
SEA	O
glycans	O
contribute	O
to	O
the	O
enhanced	O
expression	O
of	O
both	O
genes	O
.	O

To	O
further	O
establish	O
a	O
role	O
for	O
SEA	O
glycans	O
in	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
,	O
we	O
investigated	O
glycans	O
that	O
could	O
inhibit	O
the	O
binding	O
of	O
DCs	O
to	O
SEA	O
,	O
thereby	O
possibly	O
also	O
inhibiting	O
SEA	O
-	O
induced	O
SOCS1	B-GP
and	O
/	O
or	O
SHP1	B-GP
expression	O
.	O

Since	O
DC	O
survival	O
was	O
affected	O
by	O
using	O
high	O
concentrations	O
of	O
free	O
monosaccharides	O
,	O
necessary	O
to	O
enable	O
blocking	O
of	O
DC	O
binding	O
to	O
SEA	O
,	O
we	O
tested	O
a	O
panel	O
of	O
potentially	O
more	O
potent	O
monosaccharide	O
derivatives	O
for	O
their	O
ability	O
to	O
inhibit	O
binding	O
of	O
DCs	O
to	O
SEA	O
.	O

We	O
found	O
that	O
the	O
mannose	O
-	O
derivative	O
allyl	O
α	O
-	O
d	O
-	O
mannoside	O
(	O
AllMan	O
)	O
inhibited	O
the	O
binding	O
of	O
DCs	O
to	O
SEA	O
at	O
low	O
concentrations	O
,	O
in	O
contrast	O
to	O
methyl	O
α	O
-	O
D	O
-	O
mannoside	O
(	O
MeMan	O
)	O
(	O
Fig	O
5B	O
).	O

Interestingly	O
,	O
AllMan	O
also	O
inhibited	O
SEA	O
-	O
induced	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
by	O
DCs	O
,	O
whereas	O
MeMan	O
did	O
not	O
show	O
inhibition	O
at	O
a	O
similar	O
concentration	O
(	O
Fig	O
5C	O
).	O

Incubation	O
of	O
DCs	O
with	O
AllMan	O
or	O
MeMan	O
alone	O
did	O
not	O
alter	O
expression	O
levels	O
of	O
SOCS1	B-GP
or	O
SHP1	B-GP
.	O

These	O
results	O
establish	O
that	O
specific	O
SEA	O
-	O
associated	O
glycans	O
are	O
essential	O
for	O
the	O
induced	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
in	O
DCs	O
,	O
possibly	O
via	O
interaction	O
with	O
a	O
CLR	B-GP
with	O
mannose	O
-	O
specificity	O
.	O

To	O
further	O
test	O
the	O
specific	O
involvement	O
of	O
CLRs	B-GP
,	O
we	O
then	O
tested	O
whether	O
AllMan	O
could	O
block	O
the	O
binding	O
of	O
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
and	O
/	O
or	O
MR	B-GP
-	O
Fc	O
,	O
both	O
mannose	O
/	O
fucose	O
recognizing	O
CLRs	B-GP
[	O
47	O
,	O
48	O
],	O
to	O
SEA	O
.	O

We	O
found	O
that	O
low	O
concentrations	O
of	O
AllMan	O
blocked	O
binding	O
of	O
both	O
MR	B-GP
-	O
Fc	O
and	O
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
to	O
SEA	O
(	O
Fig	O
5D	O
),	O
whereas	O
higher	O
MeMan	O
concentrations	O
were	O
needed	O
to	O
achieve	O
a	O
partial	O
suppression	O
of	O
MR	B-GP
-	O
Fc	O
and	O
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
interaction	O
with	O
SEA	O
.	O

S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
induces	O
SOCS1	B-GP
and	O
SHP1	B-GP
in	O
human	B-OG
dendritic	O
cells	O
(	O
DCs	O
)	O
via	O
the	O
mannose	B-GP
receptor	I-GP
(	O
MR	B-GP
).	O

A	O
.	O

DCs	O
were	O
incubated	O
with	O
untreated	O
(	O
U	O
)	O
or	O
periodate	O
(	O
PI	O
)	O
treated	O
SEA	O
(	O
40	O
μg	O
/	O
ml	O
).	O

After	O
4h	O
,	O
SOCS1	B-GP
and	O
SHP1	B-GP
mRNA	O
levels	O
were	O
determined	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
GAPDH	B-GP
as	O
a	O
reference	O
gene	O
.	O
B	O
.	O

Binding	O
of	O
DCs	O
to	O
SEA	O
(	O
coated	O
at	O
5	O
μg	O
/	O
ml	O
)	O
was	O
determined	O
in	O
the	O
presence	O
or	O
absence	O
of	O
different	O
concentrations	O
of	O
the	O
mannose	O
derivates	O
AllMan	O
or	O
MeMan	O
.	O

Binding	O
of	O
the	O
DCs	O
to	O
SEA	O
was	O
set	O
at	O
100	O
%	O
for	O
each	O
donor	O
.	O
C	O
.	O

DCs	O
were	O
pre	O
-	O
incubated	O
for	O
2h	O
with	O
2	O
.	O
5	O
mM	O
of	O
AllMan	O
or	O
MeMan	O
,	O
followed	O
by	O
incubation	O
with	O
SEA	O
(	O
40	O
μg	O
/	O
ml	O
)	O
for	O
4h	O
.	O

Relative	O
mRNA	O
levels	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
were	O
determined	O
by	O
quantitative	O
real	O
time	O
PCR	O
using	O
GAPDH	B-GP
as	O
a	O
reference	O
gene	O
.	O
D	O
.	O

Inhibition	O
of	O
DC	B-GP
-	I-GP
SIGN	I-GP
-	O
Fc	O
and	O
MR	B-GP
-	O
Fc	O
binding	O
to	O
SEA	O
(	O
coated	O
at	O
5	O
μg	O
/	O
ml	O
)	O
was	O
detected	O
in	O
the	O
presence	O
of	O
low	O
concentrations	O
of	O
AllMan	O
(	O
0	O
.	O
5	O
–	O
5	O
mM	O
).	O
E	O
-	O
F	O
.	O

DCs	O
were	O
pre	O
-	O
incubated	O
for	O
2h	O
with	O
anti	O
-	O
MR	B-GP
,	O
anti	O
-	O
DC	B-GP
-	I-GP
SIGN1	I-GP
or	O
anti	O
-	O
DC	B-GP
-	I-GP
SIGN2	I-GP
mAbs	O
(	O
5	O
μg	O
/	O
ml	O
),	O
or	O
their	O
respective	O
isotype	O
control	O
mAbs	O
,	O
followed	O
by	O
incubation	O
with	O
SEA	O
(	O
40	O
μg	O
/	O
ml	O
)	O
for	O
4h	O
.	O

Relative	O
mRNA	O
levels	O
of	O
SOCS1	B-GP
(	O
E	O
)	O
and	O
SHP1	B-GP
(	O
F	O
)	O
were	O
determined	O
by	O
quantitative	O
real	O
time	O
PCR	O
using	O
GAPDH	B-GP
as	O
a	O
reference	O
gene	O
.	O

All	O
data	O
shown	O
are	O
derived	O
from	O
experiments	O
performed	O
in	O
duplicate	O
using	O
DCs	O
of	O
4	O
(	O
A	O
,	O
C	O
),	O
3	O
(	O
B	O
)	O
or	O
5	O
(	O
E	O
,	O
F	O
)	O
different	O
donors	O
.	O

Results	O
are	O
shown	O
as	O
the	O
mean	O
plus	O
or	O
minus	O
SEM	O
.	O

In	O
A	O
,	O
C	O
,	O
E	O
and	O
F	O
,	O
DCs	O
incubated	O
with	O
untreated	O
SEA	O
were	O
set	O
at	O
100	O
%.	O

Significance	O
is	O
indicated	O
compared	O
to	O
DCs	O
stimulated	O
with	O
untreated	O
SEA	O
as	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

To	O
discriminate	O
between	O
the	O
putative	O
involvement	O
of	O
DC	B-GP
-	I-GP
SIGN	I-GP
and	O
the	O
MR	B-GP
in	O
the	O
SEA	O
-	O
induced	O
expression	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
,	O
DCs	O
were	O
incubated	O
with	O
blocking	O
antibodies	B-GP
for	O
the	O
MR	B-GP
or	O
DC	B-GP
-	I-GP
SIGN	I-GP
prior	O
to	O
SEA	O
stimulation	O
.	O

The	O
data	O
indicate	O
that	O
the	O
blocking	O
antibodies	B-GP
to	O
MR	B-GP
,	O
but	O
not	O
isotype	O
control	O
antibodies	B-GP
,	O
significantly	O
inhibit	O
SEA	O
-	O
induced	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
.	O

By	O
contrast	O
,	O
blocking	O
of	O
DC	B-GP
-	I-GP
SIGN	I-GP
did	O
not	O
affect	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
(	O
Fig	O
5E	O
and	O
5F	O
).	O

In	O
addition	O
,	O
we	O
determined	O
whether	O
blocking	O
the	O
MR	B-GP
or	O
DC	B-GP
-	I-GP
SIGN	I-GP
using	O
similar	O
concentrations	O
and	O
conditions	O
as	O
described	O
above	O
,	O
could	O
prevent	O
the	O
potential	O
of	O
SEA	O
to	O
suppress	O
LPS	O
-	O
induced	O
production	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
.	O

However	O
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
significant	O
effect	O
(	O
data	O
not	O
shown	O
),	O
suggesting	O
that	O
a	O
more	O
complete	O
block	O
of	O
the	O
MR	B-GP
,	O
or	O
a	O
contribution	O
of	O
other	O
yet	O
unknown	O
factors	O
,	O
is	O
required	O
for	O
an	O
effective	O
suppression	O
of	O
cytokine	B-GP
production	O
.	O

In	O
summary	O
,	O
these	O
data	O
indicate	O
that	O
SEA	O
glycans	O
are	O
essential	O
to	O
induce	O
expression	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
in	O
human	B-OG
DCs	O
via	O
interaction	O
with	O
the	O
MR	B-GP
.	O

Discussion	O

Several	O
studies	O
by	O
our	O
group	O
and	O
others	O
have	O
shown	O
that	O
production	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
by	O
DCs	O
is	O
markedly	O
reduced	O
in	O
response	O
to	O
direct	O
contact	O
with	O
helminth	B-OG
antigens	O
[	O
17	O
,	O
18	O
,	O
49	O
].	O

In	O
mouse	B-OG
models	O
it	O
was	O
shown	O
that	O
oxidation	O
of	O
the	O
glycans	O
of	O
SEA	O
,	O
which	O
contains	O
many	O
glycoproteins	O
,	O
affected	O
the	O
capacity	O
of	O
SEA	O
to	O
induce	O
a	O
Th2	O
response	O
,	O
indicating	O
the	O
involvement	O
of	O
SEA	O
glycans	O
in	O
this	O
process	O
[	O
24	O
,	O
25	O
].	O

We	O
here	O
set	O
out	O
to	O
determine	O
the	O
role	O
of	O
glycan	O
determinants	O
of	O
SEA	O
in	O
the	O
modulation	O
of	O
LPS	O
-	O
induced	O
activation	O
of	O
human	B-OG
DCs	O
and	O
subsequent	O
T	O
cell	O
proliferation	O
.	O

Recently	O
it	O
was	O
shown	O
that	O
Omega	B-GP
-	I-GP
1	I-GP
,	O
a	O
major	O
glycoprotein	O
in	O
SEA	O
,	O
can	O
polarize	O
DCs	O
into	O
a	O
Th2	O
promoting	O
phenotype	O
,	O
which	O
was	O
attributed	O
to	O
both	O
the	O
glycosylation	O
and	O
RNase	B-GP
action	O
of	O
Omega	B-GP
-	I-GP
1	I-GP
[	O
20	O
,	O
32	O
].	O

To	O
discriminate	O
between	O
putative	O
glycan	O
-	O
mediated	O
effects	O
of	O
SEA	O
and	O
effects	O
associated	O
with	O
RNase	B-GP
activity	O
,	O
we	O
subjected	O
SEA	O
to	O
either	O
mild	O
periodate	O
treatment	O
to	O
oxidize	O
glycan	O
structures	O
and	O
thus	O
destroy	O
their	O
integrity	O
,	O
or	O
heated	O
the	O
SEA	O
for	O
20	O
min	O
at	O
80	O
°	O
C	O
to	O
denature	O
protein	O
structures	O
thereby	O
abolishing	O
RNase	B-GP
activity	O
.	O

Our	O
data	O
revealed	O
that	O
PI	O
-	O
sensitive	O
SEA	O
glycans	O
regulate	O
important	O
properties	O
of	O
human	B-OG
DC	O
function	O
.	O

Such	O
glycans	O
contribute	O
to	O
the	O
suppression	O
of	O
the	O
LPS	O
-	O
induced	O
secretion	O
of	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
12	I-GP
by	O
DCs	O
,	O
whereas	O
heat	O
-	O
treatment	O
of	O
these	O
products	O
abolished	O
RNase	B-GP
activity	O
,	O
but	O
did	O
not	O
affect	O
the	O
observed	O
suppressive	O
properties	O
of	O
SEA	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
PI	O
treatment	O
of	O
SEA	O
,	O
but	O
not	O
heat	O
-	O
treatment	O
,	O
reduced	O
the	O
capacity	O
of	O
SEA	O
-	O
primed	O
DCs	O
to	O
induce	O
T	O
cell	O
proliferation	O
.	O

The	O
data	O
presented	O
here	O
show	O
that	O
RNase	B-GP
activity	O
is	O
not	O
a	O
dominant	O
factor	O
within	O
total	O
SEA	O
in	O
its	O
contribution	O
to	O
the	O
described	O
anti	O
-	O
inflammatory	O
properties	O
in	O
DCs	O
,	O
whereas	O
periodate	O
sensitive	O
glycans	O
of	O
SEA	O
do	O
play	O
a	O
significant	O
role	O
.	O

The	O
novel	O
finding	O
that	O
SEA	O
increases	O
the	O
expression	O
levels	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
,	O
known	O
negative	O
regulators	O
of	O
TLR4	B-GP
signalling	O
,	O
provides	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
SEA	O
suppresses	O
TLR4	B-GP
-	O
induced	O
DC	O
activation	O
[	O
45	O
].	O

SOCS1	B-GP
belongs	O
to	O
a	O
family	O
of	O
proteins	O
that	O
inhibits	O
the	O
cytoplasmic	O
JAK	B-GP
/	O
STAT	B-GP
signalling	O
pathway	O
induced	O
in	O
TLR	B-GP
signalling	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
of	O
crucial	O
importance	O
for	O
the	O
limitation	O
of	O
inflammatory	O
responses	O
[	O
44	O
,	O
50	O
,	O
51	O
].	O

SHP1	B-GP
is	O
part	O
of	O
the	O
protein	B-GP
tyrosine	I-GP
phosphatase	I-GP
family	O
and	O
has	O
been	O
reported	O
to	O
play	O
a	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
TLR	B-GP
-	O
mediated	O
immune	O
responses	O
,	O
including	O
those	O
induced	O
via	O
TLR4	B-GP
[	O
45	O
].	O

Remarkably	O
,	O
deficient	O
macrophage	O
SHP	B-GP
-	I-GP
1	I-GP
expression	O
has	O
been	O
observed	O
in	O
MS	B-DS
patients	O
,	O
and	O
is	O
correlated	O
with	O
an	O
enhanced	O
inflammatory	O
phenotype	O
[	O
52	O
].	O

The	O
induction	O
of	O
negative	O
regulators	O
of	O
TLR	B-GP
signalling	O
may	O
be	O
a	O
strategy	O
of	O
pathogens	O
to	O
limit	O
pro	O
-	O
inflammatory	O
responses	O
.	O

Recently	O
,	O
elevated	O
SOCS3	B-GP
levels	O
were	O
observed	O
in	O
SEA	O
-	O
treated	O
DCs	O
[	O
46	O
],	O
and	O
elevated	O
SOCS1	B-GP
expression	O
was	O
observed	O
in	O
HIV	B-OG
-	O
and	O
Mycobacterium	B-OG
avium	I-OG
-	O
infected	O
patients	O
[	O
53	O
,	O
54	O
].	O

Our	O
data	O
show	O
that	O
SEA	O
strongly	O
increases	O
SOCS1	B-GP
mRNA	O
levels	O
in	O
human	B-OG
DCs	O
.	O

Whereas	O
posttranscriptional	O
regulation	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
stability	O
of	O
SOCS1	B-GP
protein	O
[	O
55	O
,	O
56	O
],	O
our	O
data	O
show	O
enhanced	O
SOCS1	B-GP
protein	O
levels	O
in	O
DCs	O
at	O
1h	O
after	O
addition	O
of	O
SEA	O
,	O
and	O
these	O
levels	O
are	O
maintained	O
for	O
several	O
hours	O
.	O

This	O
indicates	O
that	O
SEA	O
induces	O
significant	O
levels	O
of	O
stably	O
expressed	O
SOCS1	B-GP
protein	O
.	O

In	O
addition	O
,	O
SHP1	B-GP
mRNA	O
and	O
protein	O
levels	O
are	O
induced	O
by	O
stimulation	O
of	O
DCs	O
with	O
SEA	O
under	O
similar	O
conditions	O
as	O
SOCS1	B-GP
activation	O
.	O

Our	O
data	O
also	O
reveal	O
that	O
the	O
capacity	O
of	O
SEA	O
to	O
induce	O
SOCS1	B-GP
and	O
SHP1	B-GP
is	O
glycan	O
-	O
dependent	O
,	O
since	O
both	O
oxidation	O
of	O
SEA	O
glycans	O
and	O
blocking	O
the	O
binding	O
of	O
SEA	O
to	O
DCs	O
by	O
adding	O
the	O
mannose	O
-	O
mimic	O
AllMan	O
inhibit	O
the	O
induction	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
.	O

Remarkably	O
,	O
SEA	O
induces	O
a	O
simultaneous	O
upregulation	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
in	O
all	O
assays	O
,	O
indicating	O
that	O
co	O
-	O
regulation	O
of	O
both	O
negative	O
regulators	O
may	O
occur	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
SOCS1	B-GP
can	O
contribute	O
to	O
SHP1	B-GP
function	O
in	O
the	O
negative	O
regulation	O
of	O
cytokine	B-GP
signalling	O
,	O
and	O
that	O
loss	O
of	O
SOCS1	B-GP
can	O
significantly	O
compromise	O
the	O
ability	O
of	O
SHP1	B-GP
to	O
down	O
-	O
regulate	O
STAT5	B-GP
activation	O
[	O
57	O
].	O

The	O
involvement	O
of	O
SEA	O
glycans	O
in	O
the	O
modulation	O
of	O
DC	O
function	O
implicates	O
a	O
role	O
for	O
one	O
or	O
more	O
lectin	B-GP
receptors	I-GP
on	O
DCs	O
.	O

CLRs	B-GP
are	O
known	O
to	O
internalize	O
soluble	O
glycoconjugates	O
,	O
and	O
are	O
able	O
to	O
induce	O
intracellular	O
signaling	O
cascades	O
,	O
thereby	O
enhancing	O
or	O
suppressing	O
TLR	B-GP
signal	O
transduction	O
routes	O
[	O
58	O
,	O
59	O
].	O

We	O
have	O
shown	O
previously	O
that	O
DCs	O
internalize	O
SEA	O
via	O
the	O
CLRs	B-GP
DC	B-GP
-	I-GP
SIGN	I-GP
,	O
MGL	B-GP
and	O
the	O
MR	B-GP
[	O
17	O
].	O

Here	O
,	O
we	O
demonstrate	O
that	O
SOCS1	B-GP
and	O
SHP1	B-GP
induction	O
can	O
be	O
blocked	O
both	O
by	O
the	O
mannose	O
derivative	O
AllMan	O
and	O
by	O
anti	O
-	O
MR	B-GP
antibodies	B-GP
indicating	O
that	O
the	O
SEA	O
-	O
induced	O
expression	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
in	O
DCs	O
is	O
MR	B-GP
-	O
mediated	O
.	O

The	O
MR	B-GP
is	O
an	O
endocytic	B-GP
receptor	I-GP
and	O
cross	O
-	O
linking	O
of	O
the	O
MR	B-GP
can	O
enable	O
the	O
induction	O
of	O
an	O
immunosuppressive	O
phenotype	O
in	O
DCs	O
[	O
60	O
],	O
although	O
no	O
intracellular	O
signaling	O
motif	O
has	O
been	O
found	O
in	O
its	O
cytoplasmic	O
tail	O
[	O
61	O
].	O

The	O
MR	B-GP
has	O
previously	O
been	O
shown	O
to	O
play	O
a	O
significant	O
role	O
in	O
the	O
S	B-OG
.	I-OG
mansoni	I-OG
-	O
induced	O
modulation	O
of	O
pro	O
-	O
inflammatory	O
responses	O
in	O
murine	O
macrophages	O
via	O
internalization	O
of	O
excretory	O
/	O
secretory	O
material	O
released	O
by	O
cercariae	O
[	O
62	O
].	O

The	O
mechanism	O
by	O
which	O
the	O
MR	B-GP
induces	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
is	O
yet	O
to	O
be	O
determined	O
.	O

The	O
capacity	O
of	O
SEA	O
to	O
upregulate	O
mRNA	O
levels	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
via	O
the	O
MR	B-GP
is	O
difficult	O
to	O
associate	O
with	O
RNase	B-GP
activity	O
of	O
Omega	B-GP
-	I-GP
1	I-GP
.	O

It	O
would	O
be	O
possible	O
though	O
that	O
Omega	B-GP
-	I-GP
1	I-GP
or	O
Ipse	B-GP
/	I-GP
α	I-GP
-	I-GP
1	I-GP
,	O
which	O
show	O
similarity	O
in	O
their	O
glycosylation	O
and	O
are	O
both	O
internalized	O
via	O
the	O
MR	B-GP
,	O
could	O
induce	O
the	O
upregulation	O
of	O
these	O
negative	O
regulators	O
via	O
their	O
glycans	O
,	O
but	O
it	O
should	O
be	O
noted	O
that	O
more	O
glycoproteins	O
are	O
present	O
within	O
SEA	O
that	O
,	O
based	O
on	O
their	O
glycomic	O
profile	O
[	O
29	O
,	O
31	O
,	O
63	O
,	O
64	O
],	O
could	O
be	O
candidates	O
for	O
recognition	O
and	O
internalization	O
by	O
the	O
MR	B-GP
.	O

Although	O
blocking	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
with	O
anti	O
-	O
MR	B-GP
Ab	O
or	O
AllMan	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
SOCS1	B-GP
(~	O
60	O
%)	O
and	O
SHP1	B-GP
(~	O
40	O
%)	O
expression	O
,	O
we	O
did	O
not	O
observe	O
a	O
significant	O
reduction	O
in	O
the	O
suppression	O
of	O
TNFα	B-GP
production	O
of	O
LPS	O
-	O
activated	O
DCs	O
.	O

Possibly	O
,	O
the	O
MR	B-GP
blockade	O
by	O
antibody	B-GP
is	O
not	O
sufficiently	O
efficient	O
to	O
obtain	O
an	O
effect	O
on	O
the	O
level	O
of	O
cytokine	B-GP
secretion	O
,	O
since	O
a	O
complete	O
block	O
of	O
both	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
by	O
immobilization	O
of	O
SEA	O
did	O
reverse	O
the	O
suppression	O
of	O
TLR4	B-GP
-	O
induced	O
TNFα	B-GP
production	O
.	O

Alternatively	O
,	O
internalization	O
of	O
SEA	O
via	O
multiple	O
receptors	O
may	O
be	O
required	O
to	O
act	O
in	O
concerted	O
action	O
to	O
induce	O
expression	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
effectively	O
.	O

In	O
addition	O
,	O
it	O
is	O
possible	O
that	O
multiple	O
compounds	O
of	O
SEA	O
can	O
down	O
-	O
regulate	O
the	O
TLR4	B-GP
-	O
induced	O
cytokine	B-GP
production	O
via	O
different	O
pathways	O
,	O
thereby	O
acting	O
as	O
back	O
-	O
up	O
systems	O
for	O
each	O
other	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
that	O
periodate	O
sensitive	O
glycans	O
of	O
S	B-OG
.	I-OG
mansoni	I-OG
SEA	O
are	O
essential	O
for	O
suppression	O
of	O
TLR4	B-GP
-	O
induced	O
pro	O
-	O
inflammatory	O
responses	O
in	O
human	B-OG
DCs	O
.	O

SEA	O
induces	O
many	O
phenotypic	O
changes	O
in	O
DCs	O
which	O
are	O
associated	O
with	O
anti	O
-	O
inflammatory	O
properties	O
,	O
whereas	O
RNase	B-GP
activity	O
within	O
SEA	O
is	O
not	O
a	O
dominant	O
factor	O
to	O
condition	O
DCs	O
to	O
suppress	O
TLR4	B-GP
-	O
induced	O
cytokine	B-GP
production	O
and	O
T	O
cell	O
proliferation	O
.	O

In	O
addition	O
,	O
our	O
data	O
provide	O
novel	O
insights	O
in	O
the	O
mechanisms	O
by	O
which	O
SEA	O
glycans	O
act	O
and	O
implicate	O
a	O
crucial	O
role	O
of	O
the	O
MR	B-GP
in	O
the	O
SEA	O
-	O
induced	O
upregulation	O
of	O
SOCS1	B-GP
and	O
SHP1	B-GP
expression	O
in	O
DCs	O
.	O

This	O
may	O
contribute	O
to	O
the	O
capacity	O
of	O
SEA	O
to	O
down	O
-	O
regulate	O
inflammatory	O
responses	O
in	O
its	O
host	O
by	O
modulation	O
of	O
adaptive	O
T	O
cell	O
responses	O
.	O

